Skip to main content

Home

  • Drug Development
    • Our Pipeline
    • Evaluation Pipeline
    • Therapeutic areas
    • Partnering
    • Useful Links
  • News
  • Investors
    • Regulatory News
    • AIM Rule 26
      • Annual and Half Yearly Reports
      • Admission Document & Articles
    • Shareholder communications
    • Investments Calculator
    • Share Alerts
    • Share Series
    • Share price look-up
    • Analyst Research
  • About us
    • Board of Directors and Management Team
    • Strategy and Vision
    • How we work
    • Working with us
    • Collaborative Pipeline
  • Contact us

News

Breadcrumb

  1. News
Category
Suzanne Dilly - CEO ValiRx
News

ValiRx signs IP license agreement with King's College London to progress triple negative breast cancer treatment

24 Oct 2022
Stella Panu - Proposed Non-Executive Director, Valirx plc
News

ValiRx appoints NED to support growth and investment drive

19 Oct 2022
Suzanne Dilly - CEO ValiRx
Articles

Ada Lovelace Day 2022: In conversation with ValiRx’s CEO

11 Oct 2022
Videos and audiocasts

ValiRx Q&A Live Webinar Held on 29th September 2022

29 Sep 2022
ValiRx CSO
News

ValiRx bolsters drug discovery expertise with key appointment

23 Sep 2022
Videos and audiocasts

Successful evaluation of triple negative breast cancer programme

15 Jul 2022
Events and presentations

AGM & Live Q&A with Presentation Held on 30th June 2022

1 Jul 2022
Videos and audiocasts

Live Q&A Webinar With Presentation Held on 6th April 2022

6 Apr 2022
Articles

ValiRx Recognised in the Biotechnology Awards 2022

5 Apr 2022
Videos and audiocasts

ValiRx update on proposed sub-license of VAL201

23 Mar 2022
Videos and audiocasts

Growth & Innovation Forum Presentation 2022

11 Feb 2022
Videos and audiocasts

ValiRx Signs Agreement with TheoremRX

5 Jan 2022
Videos and audiocasts

ValiRx Amends License for VAL201 with Cancer Research Technology

20 Dec 2021
Videos and audiocasts

ValiRx CEO, Dr Suzanne Dilly Presents at the LSE Investor Webinar

8 Dec 2021

Pagination

  • First page First
  • Previous page Previous
  • Page 1
  • Current page 2
  • Page 3
  • Page 4
  • Next page Next
  • Last page Last
ValiRx PLC

Contact us

ValiRx Plc
Eliot Park Innovation Centre
4 Barling Way
Nuneaton, CV10 7RH
UK

Tel: +44 (0)2476 796496
Email: info@valirx.com

Registered in England and Wales

Company Number: 3916791
VAT Number: 756 3180 24

UK Registered Office Address
Stonebridge House, Chelmsford Road, Hatfield Heath, England, CM22 7BD

Links

  • Drug Development
    • Our Pipeline
    • Evaluation Pipeline
    • Therapeutic areas
    • Partnering
    • Useful Links
  • News
  • Investors
    • Regulatory News
    • AIM Rule 26
      • Annual and Half Yearly Reports
      • Admission Document & Articles
    • Shareholder communications
    • Investments Calculator
    • Share Alerts
    • Share Series
    • Share price look-up
    • Analyst Research
  • About us
    • Board of Directors and Management Team
    • Strategy and Vision
    • How we work
    • Working with us
    • Collaborative Pipeline
  • Contact us
Terms and Conditions Privacy Policy Accessibility Compliance Corporate Governance Corporate Social Responsibility

Site and its contents Copyright © ValiRx PLC 2023. All rights reserved.
Website Design and Development by Sciad Communications Ltd